Match treatments to tumors.
“Innovative solutions, Like POET™ have the potential to make an impact not only in reducing the cost of cancer treatment but also on improving the overall health, wellbeing, and quality of life of cancer patients around the world.”
– Dr. Tara M. Bryant
Chief Medical Officer, Viva Health
Each year, the Centers for Medicare & Medicaid Services (CMS) and private insurance providers spend $88 billion to treat newly diagnosed cancers. Of this, $35 billion is spent on treating just five subtypes: Breast, ovarian, lung, colorectal, and pancreatic.
And yet, about 70% of those receiving systemic therapy will be treated with drugs that do not work for them – that is nearly 3 out of every 4 patients. This is because cancer is personal: each tumor is distinct in composition and responds differently even to the same treatment. For lack of clinically relevant personalized predictive tools, current standard of care is based on generalized parameters wherein a patient is potentially exposed to several rounds of ineffective overtreatment. Inadvertently levying avoidable tolls on the quality of life of the patient and substantial financial burdens on both the patient and their health insurance providers.
There is a critical, unmet, and urgent need to match the right treatment to each patient on an individualized basis.
Match treatments to tumors.
matches treatment to tumors.
At CerFlux, we are developing low-cost Personalized Oncology Efficacy Test (POET™) technology to rapidly (7 days) match each patient with the right treatment before treatment is administered.
In the current “one-size-fits-none” approach, the patient becomes the lab; treatments are iteratively tested in the patient, causing undue pain and suffering for months, until the right regimen is found. This potentially exposes patients to several rounds of ineffective treatments resulting in considerable (avoidable) costs, lost time, possible disease progression and resistance to treatment.
Although this approach is slow, expensive, and causes considerable pain, it provides the best tumor fidelity – the intact tumor responds to treatment in its natural, physiological environment – because, after all, the patient is the lab.
Our patent-pending technology is designed to retain high-levels of tumor fidelity by evaluating efficacy of therapeutics directly on a specimen from the patient’s own tumor. Moreover, screening several therapeutics simultaneously – outside the patient – brings added benefits of high speed, low cost, zero pain and suffering to the patient, and elimination of unintended drug resistance.
Matching treatments to tumors in less than 7 days – outside the patient and before treatment begins – to identify the right treatment for each patient on an individualized basis.